The P-III (CLL14) trial evaluates the combined regimen of Venclyxto/Venclexta + obinutuzumab vs obinutuzumab & chlorambucil in 432 patients with prior untreated CLL
Results: @ median follow-up of 65.4mos., PFS remained significantly superior (median NR vs 36.4mos.), PFS rate (62.6% vs 27.0%) after 1yr. fixed-duration treatment, improvement in PFS across all risk groups, including patients with TP53 mutation/deletion & unmutated IGHV status, OS rate (81.9% vs 77.0) at 5yr. after randomization
Additionally, patients still had uMRD (18.1% vs 1.9%) @ 4yrs. after treatment completion, no new safety signals were observed. The therapy is being developed by AbbVie & Roche & is jointly commercialized by AbbVie & Genentech
Ref: PRNewswire | Image: AbbVie
